- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06215586
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) (Cycle-2-PEF)
May 10, 2024 updated by: Cardurion Pharmaceuticals, Inc.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elizabeth Moore, DNP
- Phone Number: 617-941-5130
- Email: info@cardurion.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Cardurion Investigative Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72204
- Recruiting
- Cardurion Investigative Site
-
-
California
-
Van Nuys, California, United States, 91405
- Recruiting
- Cardurion Investigative Site
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- Recruiting
- Cardurion Investigative Site
-
Miami, Florida, United States, 33137
- Recruiting
- Cardurion Investigative Site
-
-
Illinois
-
Hazel Crest, Illinois, United States, 60429
- Recruiting
- Cardurion Investigative Site
-
Peoria, Illinois, United States, 61636
- Recruiting
- Cardurion Investigative Site
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Recruiting
- Cardurion Investigative Site
-
-
Texas
-
McKinney, Texas, United States, 75069
- Recruiting
- Cardurion Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Is an adult male or female patient ≥ 18 years of age
Has evidence in the medical history supporting a diagnosis of clinical HF syndrome, NYHA functional class II to III, with the duration of at least 6 months prior to the time of Screening. The HF syndrome is defined by documentation of 1 or more of the following:
- At least 1 of the typical symptoms due to HF such as dyspnea and/or fatigue limiting exercise capacity;
- At least 1 of the typical signs of HF such as peripheral edema, elevated jugular venous pressure, pulmonary crackles; or
- Hospitalization, emergency department visit, or outpatient visit for HF requiring intravenous (IV) or subcutaneous (SQ) diuresis within the past 12 months.
- Has ejection fraction (EF) >40% and left atrial enlargement by transthoracic echocardiogram (TTE) performed and interpreted locally at the time of Screening;
- Has NT-proBNP level ≥ 300 pg/mL at the time of Screening. Patients with atrial fibrillation or flutter at the time of Screening are required to have an NT proBNP level of ≥500 pg/mL at the time of Screening;
- Is on stable optimized doses of guideline-directed HF therapy, per Investigator's clinical judgment, for a minimum of 4 weeks prior to the time of Screening and during the Screening Period, with no planned changes after randomization; Has had no addition of new guideline-directed HF therapy within the 3 months prior to the time of Screening or during the Screening Period;
Exclusion Criteria:
- Has documented EF ≥ 60% by TTE within 6 months of the time of Screening or during the Screening Period;
- Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 60 days of the time of Screening or during the Screening Period;
- Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration;
- Has elective interventions (eg, percutaneous coronary intervention, device implantations, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study;
- Has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, or carotid angioplasty within 60 days of the time of Screening or during the Screening Period;
- Has had a prior or planned orthotopic heart transplantation;
- Has presence of or plan for mechanical circulatory support;
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Tablets administered orally
|
Experimental: Tovinontrine (CRD-750)
|
Tablets administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in biomarkers from Baseline to Week 12 - NT-proBNP
Time Frame: Baseline to Week 12
|
The percent change in plasma NT-proBNP (Dose Cohort 3 versus placebo) will be calculated from Baseline to Week 12 using an ANCOVA model.
If a statistically significant reduction in plasma NT-proBNP is detected (2-sided alpha=0.05), the next analysis will compare Dose 2 versus placebo at the (2-sided alpha = 0.05 level).
If statistically significant, the next analysis will compare Dose 1 versus placebo.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in biomarkers at week 12 by treatment group - cGMP
Time Frame: Baseline to Week 12
|
The percent change in urine and plasma cGMP from Baseline to Week 12 will be analyzed using ANCOVA and MMRM models by treatment group.
|
Baseline to Week 12
|
Change in biomarkers at week 12 by treatment group - BNP
Time Frame: Baseline to Week 12
|
The percent change in BNP from Baseline to Week 12 will be analyzed using an ANCOVA model to evaluate individual dose comparisons.
|
Baseline to Week 12
|
Change in the biomarker ratio at Week 12 - NT-proBNP
Time Frame: Baseline to Week 12
|
The change in the urine and plasma cGMP to NT-proBNP ratio at week 12 will be calculated for each treatment group
|
Baseline to Week 12
|
Change in the biomarker ratio at Week 12 - BNP
Time Frame: Baseline to Week 12
|
The percent change in the urine and plasma cGMP to BNP ratio from Baseline to Week 12 will be calculated for each treatment group
|
Baseline to Week 12
|
Kansas City Cardiomyopathy Questionnaire-23-Clinical Summary Score
Time Frame: Baseline to Week 12
|
Scaled 0 to 100 where lower scores represent worse health status than higher scores
|
Baseline to Week 12
|
New York Heart Association Classification
Time Frame: Baseline to Week 12
|
Class I to IV are possible with a higher classification representing worsening heart failure status
|
Baseline to Week 12
|
Treatment Emergent Adverse Events (TEAEs)
Time Frame: Baseline to Week 12
|
The number of participants with TEAEs including drug related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation will be assessed.
The incidence of AEs will be presented by system organ class and preferred term according to the Medical Dictionary of Regulatory Activities.
|
Baseline to Week 12
|
Changes in laboratory assessments
Time Frame: Baseline to Week 12
|
Number of participants with normal/ abnormal values at Baseline compared to normal/ abnormal values post-Baseline will be assessed for hematology, serum chemistry and urinalysis.
Descriptive statistics of clinical laboratory assessment results and the change from Baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Changes in vital sign measurement: systolic and diastolic blood pressure
Time Frame: Baseline to Week 12
|
Change from Baseline to Week 12 will be assessed for systolic and diastolic blood pressure (mmHg).
Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Changes in vital sign measurement: pulse rate
Time Frame: Baseline to Week 12
|
The change from Baseline to Week 12 will be assessed for pulse rate (bpm).
Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Changes in vital sign measurement: respiratory rate
Time Frame: Baseline to Week 12
|
The change from Baseline to Week 12 will be assessed for respiratory rate (breaths/min).
Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Changes in vital sign measurement: body temperature
Time Frame: Baseline to Week 12
|
The change from Baseline to Week 12 will be assessed for body temperature.
Descriptive statistics of vital signs and the change from Baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Changes in physical examination
Time Frame: Baseline to Week 12
|
General physical exams will be carried out to detect any abnormalities in the cardiovascular, respiratory, and other body systems.
Non-pre-existing abnormal physical examinations will be summarized by dose cohort and visit.
|
Baseline to Week 12
|
Changes in 12-lead electrocardiogram (ECG) measurements
Time Frame: Baseline to Week 12
|
Number of participants who have normal/abnormal 12-lead ECG measurements at Baseline will be compared to normal/abnormal 12-lead ECG measurement post Baseline.
Descriptive statistics of 12-lead ECG data and the change from baseline will be presented by dose cohort and visit.
|
Baseline to Week 12
|
Assessment of pharmacokinetics (PK): PK effect on NT-proBNP
Time Frame: Baseline to Week 12
|
The plasma concentrations will be evaluated in the PK Population.
The plasma concentration of tovinontrine will be summarized by dose cohort and visit.
The correlation of plasma concentration with percent change in plasma NT-proBNP will be evaluated using Pearson's correlation coefficient.
|
Baseline to Week 12
|
Assessment of pharmacokinetics (PK): PK effect on plasma cGMP
Time Frame: Baseline to Week 12
|
The plasma concentrations will be evaluated in the PK Population.
The plasma concentration of tovinontrine will be summarized by dose cohort and visit.
The correlation of plasma concentration with percent change in plasma cGMP will be evaluated using Pearson's correlation coefficient.
|
Baseline to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Elizabeth Moore, DNP, Senior Director, Clinical Research Cardurion
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2024
Primary Completion (Estimated)
October 1, 2025
Study Completion (Estimated)
October 1, 2025
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
January 19, 2024
First Posted (Actual)
January 22, 2024
Study Record Updates
Last Update Posted (Actual)
May 13, 2024
Last Update Submitted That Met QC Criteria
May 10, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRD-750-202
- 2023-508737-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
Xiao-dong ZhuangRecruitingValvular Heart DiseaseChina
-
University College, LondonBritish Heart Foundation; Horizon 2020 - European CommissionRecruitingValvular Heart DiseaseUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States